Petosemtamab
-
Genmab to Acquire Merus: Expanding Pipeline and Transitioning to Wholly Owned Model
Genmab will acquire Merus for $97.00 per share in cash, a deal valued at approximately $8.0 billion. This acquisition adds petosemtamab, a late-stage asset with Breakthrough Therapy Designations for head and neck cancer, to Genmab’s portfolio. Petosemtamab has shown promising Phase 2 data and is currently in Phase 3 trials. Genmab anticipates the acquisition accelerating its business model transition, broadening revenue streams and being accretive to EBITDA by the end of 2029. The deal is expected to close in early 2026, pending customary approvals.
